Abstract: A shampoo formulation is provided, comprising: dermatologically acceptable vehicle; dermatologically acceptable silicone; a dermatologically acceptable hair cleaning surfactant; a deposition aid polymer, wherein the deposition aid polymer is a modified carbohydrate polymer, comprising a dextran base polymer functionalized with (i) quaternary ammonium groups of formula (II) bound to a pendent oxygen on the dextran base polymer (II) wherein is a pendent oxygen on the dextran base polymer, wherein X is a divalent linking group; wherein each R2 is independently selected from a C1-4 alkyl group; and wherein R3 is a linear or branched C1-16 alkyl group; and (ii) hydrophobic substituents of formula (III) bound to a pendent oxygen on the dextran base polymer (III) wherein is a pendent oxygen on the dextran base polymer; wherein Z is a divalent linking group; wherein a is 0 or 1; and wherein each R5 is a linear or branched C6-22 alkyl group.

Abstract: A fixative polymer is provided, comprising: structural units of monoethylenically unsaturated C1-12 alkyl (meth)acrylate monomer; structural units of monoethylenically unsaturated carboxylic acid containing monomer; structural units of monoethylenically unsaturated hydroxy functionalized C1-16 alkyl (meth)acrylate monomer; and structural units of carbosiloxane monomer of formula (I) wherein a is 0 to 3; wherein d is 0 or 1; wherein R1 is hydrogen, C1-10 alkyl, aryl, —OSi(R9)3 or —X—SiOSi(R9)3; wherein R2 and R9 are hydrogen or C1-10 alkyl; wherein R8 is —OSi(CH3)2OSi(CH3)3; wherein Y is formula (II), (III), (IV) or (V) wherein R4, R6 and R10 are hydrogen or C1-4 alkyl; wherein X, R3 and R5 are a divalent linking group; wherein R7 is a C1-10 alkyl group; wherein b is 0 to 4 and wherein c is 0 or 1.

Abstract: A silicone-(meth) acrylate copolymer and methods for the preparation and use of the copolymer are provided. The copolymer is soluble in ethanol under ambient conditions. The copolymer, or homogeneous ethanol solution thereof, may be used as a film forming agent in a personal care composition, such as a foundation.

Abstract: This disclosure describes, in one aspect, a composition that generally includes an xNA molecule comprising at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating cardiac disease. Generally, the method includes administering to a subject a composition that includes an xNA molecule having at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function, and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method for evaluating the efficacy of treatment of cardiac disease. Generally, the method includes administering to a subject a composition that includes a first xNA molecule comprising a predetermined length in an amount effective to increase myocyte relaxation, then selecting a predetermined length of a second xNA molecule for at least one subsequent treatment.

Abstract: This disclosure describes, in one aspect, a composition that generally includes an xNA molecule comprising at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating cardiac disease. Generally, the method includes administering to a subject a composition that includes an xNA molecule having at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function, and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method for evaluating the efficacy of treatment of cardiac disease. Generally, the method includes administering to a subject a composition that includes a first xNA molecule comprising a predetermined length in an amount effective to increase myocyte relaxation, then selecting a predetermined length of a second xNA molecule for at least one subsequent treatment.

Abstract: This disclosure describes, in one aspect, a composition that generally includes an xNA molecule comprising at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating cardiac disease. Generally, the method includes administering to a subject a composition that includes an xNA molecule having at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function, and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method for evaluating the efficacy of treatment of cardiac disease. Generally, the method includes administering to a subject a composition that includes a first xNA molecule comprising a predetermined length in an amount effective to increase myocyte relaxation, then selecting a predetermined length of a second xNA molecule for at least one subsequent treatment.